Rangeley Capital LLC Takes $761,000 Position in Inhibrx, Inc. (NASDAQ:INBX)

Rangeley Capital LLC bought a new position in shares of Inhibrx, Inc. (NASDAQ:INBX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 49,401 shares of the company’s stock, valued at approximately $761,000. Rangeley Capital LLC owned approximately 0.34% of Inhibrx at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. HighTower Advisors LLC bought a new stake in shares of Inhibrx in the fourth quarter worth about $12,039,000. Slotnik Capital LLC purchased a new position in Inhibrx during the 4th quarter valued at approximately $5,975,000. Geode Capital Management LLC bought a new stake in Inhibrx in the 4th quarter worth approximately $3,930,000. Bank of New York Mellon Corp purchased a new stake in shares of Inhibrx during the 4th quarter worth approximately $792,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Inhibrx during the 4th quarter valued at approximately $503,000. Institutional investors own 82.46% of the company’s stock.

Inhibrx Stock Up 0.4 %

INBX stock opened at $14.10 on Thursday. Inhibrx, Inc. has a 12 month low of $10.80 and a 12 month high of $35.42. The company has a 50-day moving average price of $13.38 and a 200 day moving average price of $14.57.

Inhibrx (NASDAQ:INBX) last released its earnings results on Monday, March 17th. The company reported ($3.09) earnings per share for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The firm had revenue of $0.10 million during the quarter. As a group, research analysts forecast that Inhibrx, Inc. will post 104.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, JMP Securities reissued a “market perform” rating on shares of Inhibrx in a research note on Wednesday, January 22nd.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.